RJ-4964

N/A

Report date: 2022/12/30 17:56:28
NME

Base Information

Drug NameRJ-4964
Drug Alias NameRJ-4964RJ4964
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSpleen tyrosine kinase inhibitors
TargetsSpleen tyrosine kinase
Therapy Area/IndicationsPurpura, Thrombocytopenic, IdiopathicLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing Ruijie Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Ruijie Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsPurpura, Thrombocytopenic, IdiopathicLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A